Clinical Trials

58 enrolled

Phase EARLY_PHASE1 Unknown

Recurrence, Lymphoma, T-Cell, Peripheral

NCT04696705 2021-01-06

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

10 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT04489264 2020-12-04

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

60 enrolled

Lymphoma, T-Cell, Peripheral

NCT03921879 2020-10-23

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

50 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02445404 2020-10-22

Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

134 enrolled

Lymphoma, T-Cell, Peripheral

NCT04457830 2020-10-22

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

105 enrolled

Lymphoma, T-Cell, Peripheral

NCT04040491 2020-05-12

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Phase 4 Unknown

Lymphoma, T-Cell, Peripheral

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

44 enrolled

Phase EARLY_PHASE1 Unknown

Recurrence, Lymphoma, T-Cell, Peripheral

NCT04028440 2019-09-26

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

6 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral

NCT04061772 2019-08-20

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

54 enrolled

Lymphoma, T-Cell, Peripheral

NCT04008394 2019-08-07

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

50 enrolled

Hodgkin Disease, Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT02495415 2019-07-23

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

140 enrolled

Lymphoma, T-Cell, Peripheral

NCT03631862 2018-08-15

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Phase 4 Unknown

Lymphoma, T-Cell, Peripheral

NCT03553537 2018-06-12

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase 3 Unknown

Lymphoma, T-Cell, Peripheral

NCT02753543 2017-11-14

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

33 enrolled

Lymphoma, T-Cell, Peripheral

NCT03321890 2017-10-26

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

102 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03268889 2017-08-31

CHOP

Phase NA Unknown

39 enrolled

Lymphoma, T-Cell, Peripheral

NCT03150602 2017-05-12

A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy

Phase 4 Unknown

22 enrolled

Lymphoma, T-Cell, Peripheral, Disease Progression

NCT03000738 2017-03-31

The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT03051581 2017-02-13

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma

Phase NA Unknown

80 enrolled

Lymphoma, T-Cell, Peripheral

NCT03023358 2017-01-18

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Phase 3 Unknown

174 enrolled

Lymphoma, T-Cell, Peripheral

NCT02944812 2016-10-26

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

12 enrolled

Lymphoma, T-Cell, Peripheral

NCT02856997 2016-08-05

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

35 enrolled

Lymphoma, T-Cell, Peripheral

NCT02404571 2016-07-26

GDP in Frontline Chemotherapy for Patients With PTCL-NOS

28 enrolled

Lymphoma, T-Cell, Peripheral

NCT02364466 2015-02-18

Cohort of Peripheral T Cell Lymphoma

Classical hematologyLymphoid

200 enrolled

Lymphoma, T-Cell, Peripheral, Febrile Neutropenia

NCT01016990 2014-01-10

Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia

DermatologicLymphoidOther hematologic neoplasm

52 enrolled

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01307592 2014-01-10

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

70 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00562068 2013-08-26

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

30 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01470066 2011-11-11

Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas

80 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00840385 2010-09-15

FAD

30 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00974324 2010-09-15

PTCL

15 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00299351 2006-03-06

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

8 enrolled